Three-year-old Cellerix has raised more than â‚¬27 million ($38 million) to advance its work on adult stem cell therapies. The Spanish company has a stem cell therapy slated to begin Phase III later this year. Life Sciences Partners and Ventech co-led the round, and were joined by Roche Venture Fund, Novartis Venture Fund and Ysios Capital Partners.
- check out the report from Private Equity Hub
The Top 5 VC deals of the first half of 2007. Report